JP2018530587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530587A5 JP2018530587A5 JP2018519312A JP2018519312A JP2018530587A5 JP 2018530587 A5 JP2018530587 A5 JP 2018530587A5 JP 2018519312 A JP2018519312 A JP 2018519312A JP 2018519312 A JP2018519312 A JP 2018519312A JP 2018530587 A5 JP2018530587 A5 JP 2018530587A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- optionally substituted
- cyano
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242881P | 2015-10-16 | 2015-10-16 | |
| US62/242,881 | 2015-10-16 | ||
| PCT/US2016/057405 WO2017066793A1 (en) | 2015-10-16 | 2016-10-17 | Mrna cap analogs and methods of mrna capping |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530587A JP2018530587A (ja) | 2018-10-18 |
| JP2018530587A5 true JP2018530587A5 (enExample) | 2019-11-28 |
Family
ID=57219027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519312A Pending JP2018530587A (ja) | 2015-10-16 | 2016-10-17 | ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190225644A1 (enExample) |
| EP (1) | EP3362460A1 (enExample) |
| JP (1) | JP2018530587A (enExample) |
| AU (1) | AU2016340183A1 (enExample) |
| CA (1) | CA3001014A1 (enExample) |
| WO (1) | WO2017066793A1 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2914225T3 (es) * | 2015-10-16 | 2022-06-08 | Modernatx Inc | Análogos de cap de ARNm con enlace de fosfato modificado |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| EP3529255A1 (en) | 2016-10-19 | 2019-08-28 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
| US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
| US11692002B2 (en) | 2017-11-08 | 2023-07-04 | CureVac SE | RNA sequence adaptation |
| WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
| JP7417529B2 (ja) * | 2018-03-07 | 2024-01-18 | サノフイ | ヌクレオチド前駆体、ヌクレオチド類似体およびこれを含むオリゴマー化合物 |
| EP3765477A1 (en) * | 2018-03-15 | 2021-01-20 | BioNTech RNA Pharmaceuticals GmbH | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| SG11202008225PA (en) | 2018-04-17 | 2020-11-27 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| CN108484690B (zh) * | 2018-05-16 | 2021-04-30 | 新乡拓新药业股份有限公司 | 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法 |
| EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
| GB2592505B (en) * | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| US12492425B2 (en) | 2018-12-21 | 2025-12-09 | CureVac SE | Methods for RNA analysis |
| CA3118034A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
| WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| CN114072407A (zh) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | 靶向prmt5的化合物 |
| WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
| CN112390838A (zh) * | 2019-08-14 | 2021-02-23 | 斯微(上海)生物科技有限公司 | 一种改性核苷及其合成方法 |
| JP2022544412A (ja) | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 |
| KR20220057566A (ko) * | 2019-09-05 | 2022-05-09 | 미토레인보우 테라퓨틱스, 인크. | 미토콘드리아 dna 고갈 장애의 치료 |
| EP4076647A1 (en) | 2019-12-20 | 2022-10-26 | CureVac AG | Lipid nanoparticles for delivery of nucleic acids |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| JP7793525B2 (ja) | 2020-02-04 | 2026-01-05 | キュアバック エスイー | コロナウイルスワクチン |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4106876B1 (en) | 2020-02-18 | 2025-09-17 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
| CN116322758A (zh) | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| CN116368226A (zh) * | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| US20240181038A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
| KR102923359B1 (ko) | 2021-04-16 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| JP2024523237A (ja) | 2021-06-18 | 2024-06-28 | ホンジーン バイオテック コーポレイション | 官能化されたｎ－アセチルガラクトサミンヌクレオシド |
| WO2023007019A1 (en) * | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| EP4396193A4 (en) | 2021-08-30 | 2025-07-02 | Hongene Biotech Corp | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES |
| EP4395748A1 (en) | 2021-09-03 | 2024-07-10 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| US20240398933A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4448540A1 (en) | 2021-12-15 | 2024-10-23 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| JP2025507751A (ja) | 2022-03-01 | 2025-03-21 | クリスパー・セラピューティクス・アクチェンゲゼルシャフト | アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物 |
| WO2023180904A1 (en) | 2022-03-21 | 2023-09-28 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| CN115057903B (zh) * | 2022-06-22 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2023246860A1 (zh) * | 2022-06-22 | 2023-12-28 | 江苏申基生物科技有限公司 | 一种起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115109110B (zh) * | 2022-06-22 | 2024-07-12 | 江苏申基生物科技有限公司 | 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN114853836B (zh) * | 2022-06-24 | 2024-05-14 | 江苏申基生物科技有限公司 | 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| JP2025532686A (ja) | 2022-09-26 | 2025-10-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | インフルエンザウイルスワクチン |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| CN116143854A (zh) * | 2022-11-08 | 2023-05-23 | 江苏申基生物科技有限公司 | 一种核糖环修饰的mRNA帽类似物及其制备方法和应用 |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| CN115947759A (zh) * | 2022-12-13 | 2023-04-11 | 安徽大学 | 一种治疗新冠药物瑞德西韦的制备方法 |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| EP4701658A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| EP4701657A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| CN116554250A (zh) * | 2023-05-04 | 2023-08-08 | 江苏申基生物科技有限公司 | 一种pace结构修饰的帽类似物及其应用 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| CN121605199A (zh) | 2023-05-16 | 2026-03-03 | 科威瓦克制造有限公司 | 使用dna珠粒的改进的rna的体外转录 |
| WO2024245907A1 (en) | 2023-05-26 | 2024-12-05 | CureVac SE | Cancer antigens |
| WO2024260570A1 (en) | 2023-06-23 | 2024-12-26 | CureVac SE | Nucleic acid encoded antibodies |
| WO2025005647A1 (ko) * | 2023-06-26 | 2025-01-02 | 전북대학교산학협력단 | 새로운 변형 트리뉴클레오티드 캡핑 유도체와 캡핑 유도체가 도입된 mRNA |
| WO2025022290A1 (en) | 2023-07-21 | 2025-01-30 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| CN116987137B (zh) * | 2023-09-26 | 2024-01-02 | 江苏申基生物科技有限公司 | 一种加帽化合物及其在mRNA加帽中的应用 |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025141025A2 (en) * | 2023-12-26 | 2025-07-03 | Eleven Therapeutics Ltd | Novel capping strategies for mrna 5'cap |
| WO2025181704A2 (en) | 2024-02-27 | 2025-09-04 | Crispr Therapeutics Ag | Rt editing compositions and methods |
| WO2025186726A1 (en) | 2024-03-05 | 2025-09-12 | Crispr Therapeutics Ag | Modulating expression of agt (angiotensinogen) gene |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6111095A (en) * | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US5962271A (en) * | 1996-01-03 | 1999-10-05 | Cloutech Laboratories, Inc. | Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| JP2001521759A (ja) | 1997-11-12 | 2001-11-13 | ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド | ヒトアミロイド前駆体タンパク質遺伝子の翻訳エンハンサーエレメント |
| US6429301B1 (en) * | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| EP1073730A1 (en) * | 1998-04-17 | 2001-02-07 | Whitehead For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| BR0107930A (pt) | 2000-01-28 | 2004-06-15 | Scripps Research Inst | Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos |
| US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) * | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| RS63964B1 (sr) * | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| WO2007025008A2 (en) | 2005-08-24 | 2007-03-01 | The Scripps Research Institute | Translation enhancer-element dependent vector systems |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| WO2008016473A2 (en) * | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8859229B2 (en) * | 2007-02-02 | 2014-10-14 | Yale University | Transient transfection with RNA |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| SG10201408164XA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| CA2710534C (en) | 2008-01-31 | 2018-09-04 | Curevac Gmbh | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
| CN102123716B (zh) * | 2008-04-03 | 2013-09-18 | 春堤公司 | 用于治疗病毒感染的化合物和方法 |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| SG174150A1 (en) * | 2009-02-24 | 2011-10-28 | Scripps Research Inst | Reengineering mrna primary structure for enhanced protein production |
| EP2281579A1 (en) * | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| ME03091B (me) * | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EP2558571A4 (en) * | 2010-04-16 | 2014-09-24 | Immune Disease Inst Inc | DELAYED POLYPEPTIDE EXPRESSION FROM MODIFIED SYNTHETIC RNAS AND USES THEREOF |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| JP2013531634A (ja) | 2010-05-24 | 2013-08-08 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質 |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
| JP5948327B2 (ja) | 2010-07-30 | 2016-07-06 | キュアヴァック アーゲー | トランスフェクションおよび免疫刺激のためのジスルフィド架橋されたカチオン性成分との核酸の複合体形成 |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013059475A1 (en) * | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| CN108929880A (zh) | 2012-03-27 | 2018-12-04 | 库瑞瓦格股份公司 | 包含5′toputr的人工核酸分子 |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| CN104220599A (zh) | 2012-03-27 | 2014-12-17 | 库瑞瓦格有限责任公司 | 人工核酸分子 |
| US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| US9597380B2 (en) * | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| CN105073135A (zh) | 2013-02-22 | 2015-11-18 | 库瑞瓦格有限责任公司 | 疫苗接种和抑制pd-1途径的组合 |
| JP2016515216A (ja) * | 2013-03-14 | 2016-05-26 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのキャップ効率の定量的評価 |
| WO2015002667A1 (en) | 2013-07-01 | 2015-01-08 | Myq, Inc. | A location regulated point-of-sale system and enhancements |
| US20150050738A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating rna |
| SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| SG11201510748PA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| MX2016002153A (es) | 2013-08-21 | 2017-03-01 | Curevac Ag | Composicion y vacuna para tratar cancer de prostata. |
| WO2015051173A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc | Polynucleotide molecules and uses thereof |
| EP3052511A4 (en) * | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| GB201320962D0 (en) * | 2013-11-27 | 2014-01-08 | Globalacorn Ltd | Compositions |
| WO2015101414A2 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
| JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
| ES2914225T3 (es) * | 2015-10-16 | 2022-06-08 | Modernatx Inc | Análogos de cap de ARNm con enlace de fosfato modificado |
-
2016
- 2016-10-17 JP JP2018519312A patent/JP2018530587A/ja active Pending
- 2016-10-17 EP EP16788887.4A patent/EP3362460A1/en not_active Withdrawn
- 2016-10-17 WO PCT/US2016/057405 patent/WO2017066793A1/en not_active Ceased
- 2016-10-17 CA CA3001014A patent/CA3001014A1/en not_active Abandoned
- 2016-10-17 US US15/768,193 patent/US20190225644A1/en not_active Abandoned
- 2016-10-17 AU AU2016340183A patent/AU2016340183A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530587A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| JP2019513778A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| WO2007091009A3 (en) | Preparation of delmopinol | |
| JP2016525136A5 (enExample) | ||
| JP2017519796A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| JP2012504608A5 (enExample) | ||
| EA201800118A1 (ru) | Фосфорамидатное нуклеозидное пролекарство для лечения вирусных и раковых заболеваний, способы его получения и использования | |
| JP2017052761A5 (enExample) | ||
| CA2654315A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use | |
| JP2020063289A5 (enExample) | ||
| JP2016535769A5 (enExample) | ||
| JP2015535847A5 (enExample) | ||
| TW201502124A (zh) | 製備苯并咪唑衍生物之方法 | |
| MA40480B1 (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| JP2006225406A5 (enExample) | ||
| BR112022007102A2 (pt) | Métodos para a preparação de ácido 5-bromo-2-(3-cloro-piridin-2-il)-2h-pirazol-3-carboxílico | |
| RU2008136892A (ru) | Способ получения соединения 5-алкокси-4-гидроксиметилпиразола | |
| WO2014008838A4 (zh) | 芳基取代甲基连接的双吲哚乙酸衍生物及其制备方法和应用 | |
| JPWO2021174170A5 (enExample) | ||
| JP2018508537A5 (enExample) | ||
| JP2007506659A5 (enExample) |